Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 5/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | BCL6 | P41182 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428542 | 0.83 | AURKA (0.46) | AURKAAURKBALDH1A1HSD17B10KDM4E | |
| SCHEMBL14412453 | 0.83 | P2RX3 (0.35) | P2RX3MEN1MAPTKMT2A | |
| SCHEMBL430604 | 0.81 | AIMP2 (0.47) | AURKAAURKBHSD17B10PIK3CA | |
| SCHEMBL16822437 | 0.81 | ATR (0.34) | GBA1AURKAAURKBRIPK1PIK3CA | |
| SCHEMBL429008 | 0.80 | HSD17B10 (0.40) | GBA1AURKAAURKBALDH1A1MAPT | |
| SCHEMBL430146 | 0.77 | AURKA (0.37) | GBA1AURKAAURKBRIPK1ALDH1A1 | |
| SCHEMBL2672779 | 0.77 | CSF1R (0.43) | ALDH1A1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL3324305 | 0.72 | TYK2 (0.41) | AURKAAURKBHSD17B10PIK3CA | |
| SCHEMBL426346 | 0.71 | AURKA (0.46) | AURKAAURKBPIK3CA | |
| SCHEMBL425505 | 0.71 | GRM4 (0.45) | GBA1ALDH1A1GAAMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687004-A4 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2009-04-08 | — | — | EP | claimed |
| JP-2007510747-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687004-A2 | PYRIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338951-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167300-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | P2RX3 407/4885GBA1 1336/4885AURKA 1791/4885 |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | P2RX3 1763/4885GBA1 2127/4885AURKA 4145/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | P2RX3 3059/4885GBA1 1510/4885AURKA 4825/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | P2RX3 407/4885GBA1 1336/4885AURKA 1791/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | P2RX3 3059/4885GBA1 1510/4885AURKA 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.